logo-loader
viewFutura Medical PLC

Futura Medical shifts focus to MED2002 treatment as clinical trial set to begin

Futura

Futura Medical PLC's (LON:FUM) James Barder tells Proactive the company has seen a very good year of progress with its  MED2002 erectile dysfunction gel as the company reports its half year results.

Futura expects to dose the first patient in the late-stage study of the gel within the next few weeks as part of a trial involving 1,000 men suffering from ED, with headline data expected by the end of 2019.

Quick facts: Futura Medical PLC

Price: 16.25 GBX

AIM:FUM
Market: AIM
Market Cap: £39.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical's James Barder says regulatory submissions for MED3000 remain...

Futura Medical PLC's (LON:FUM) James Barder tells Proactive London's Andrew Scott they've seen little impact from the coronavirus lockdown and that regulatory submissions for its erectile dysfunction treatment remain on track. The treatment is MED3000 - a fast-acting gel that will be targeted...

1 week, 4 days ago

2 min read